Amarin Corp Plc (AMRN)

[dogn]

Gilead NASH combo drug trial Vascepa arm

I was wondering after re-reading the Nov. 2019 $20B buyout hype article [https://www.fiercepharma.com/pharma/amarin-for-20b-novartis-medco-deal-drives-fresh-buyout-rumors-for-fish-oil-derivative] when Amarin was at ~$21/share if results were ever reported or discussed here for the mentioned Gilead NASH combo drug trial that included Vascepa in Cohort 12 (FIR 20 mg + CILO 30 mg + VAS 2g).

https://clinicaltrials.gov/ct2/show/results/NCT02781584

Results 1st posted Feb. 2, 2022; Last update March 16, 2022

I guess it’s over and nothing spectacular or disastrous involving the IPE arm occurred.

Anyone follow this?

From Results tab: 30 participants on Vascepa completed. Lowest non-serious adverse event rate among all cohorts. 1 discontinued with adverse event (non/cardiac chest pain).

But otherwise cannot determined outcome of trial. There’s a June 2021 poster listed as last report (and miscellaneous 2019 and earlier reports I guess preceded the trial completion):

Lawitz E, Bhandari BR, Ruane P, Kohli A, Harting E, Jia C, et al. Fenofibrate is Safe and Mitigates Increases in Serum Triglycerides in NASH Patients Treated with the Combination of the ACC Inhibitor Firsocostat and the FXR Agonist Cilofexor: A Randomized Trial. Poster presented at: The European Association for the Study of the Liver (EASL): International Liver Congress; June 23-26, 2021; Virtual Meeting.